The litigation centers on allegations that Embecta executives issued misleading guidance regarding the firm's financial health. Specifically, the complaint claims management described the company's pen needle business as "incredibly resolute" just weeks before reporting a significant revenue shortfall. On May 5, 2026, the company revealed a 14% decline in quarterly revenue—far exceeding previous projections—which triggered a 57.8% drop in share price from $9.25 to $3.90 in a single trading session.
Faruqi & Faruqi, LLP is currently representing shareholders who suffered losses during this period. While the August 17 deadline applies to those seeking the role of lead plaintiff, investors are reminded that they do not need to assume a leadership role to participate in a potential recovery. The firm encourages affected parties, including former employees and whistleblowers, to contact partner Josh Wilson to review their legal options and trading records.
Comments (0)
No comments yet. Be the first!